PURPOSE: Neuroendocrine tumors (NET) of the ileum/jejunum are rare and may require different treatment options to provide long-term survival. The purpose of the study was to evaluate the outcome of surgery for ileojejunal NET. METHODS: A database of patients that underwent surgery for ileojejunal NETs between 1999 and 2010 was retrospectively analyzed regarding the clinical characteristics, surgical therapy, survival and prognostic factors. RESULTS: Only six of 97 patients with ileojejunal NET who underwent surgery had localized tumors (stage I/II), 29 had lymph node involvement (stage III) and 62 had distant metastases (stage IV) at the initial presentation. All stage I/II tumors were cured, in comparison to 69% of stage III and 0% of stage IV tumors (p = 0.01). Palliative surgery in combination with sequential multimodal treatment regimens resulted in a 5-year survival rate of 63% in patients with stage IV tumors. A multivariate analysis showed that incomplete resection (HR 2.87; CI 1.18-6.98; p = 0.04) and distant metastases (HR 5.39; 95% CI 1.23-23.57; p = 0.02) were associated with worse disease-specific survival. CONCLUSIONS: Localized and regionally restricted ileojejunal NETs have an excellent prognosis after surgical treatment. Although stage IV tumors cannot be cured, an aggressive surgical approach in combination with medical or interventional treatment can provide long-term survival.
PURPOSE:Neuroendocrine tumors (NET) of the ileum/jejunum are rare and may require different treatment options to provide long-term survival. The purpose of the study was to evaluate the outcome of surgery for ileojejunal NET. METHODS: A database of patients that underwent surgery for ileojejunal NETs between 1999 and 2010 was retrospectively analyzed regarding the clinical characteristics, surgical therapy, survival and prognostic factors. RESULTS: Only six of 97 patients with ileojejunal NET who underwent surgery had localized tumors (stage I/II), 29 had lymph node involvement (stage III) and 62 had distant metastases (stage IV) at the initial presentation. All stage I/II tumors were cured, in comparison to 69% of stage III and 0% of stage IV tumors (p = 0.01). Palliative surgery in combination with sequential multimodal treatment regimens resulted in a 5-year survival rate of 63% in patients with stage IV tumors. A multivariate analysis showed that incomplete resection (HR 2.87; CI 1.18-6.98; p = 0.04) and distant metastases (HR 5.39; 95% CI 1.23-23.57; p = 0.02) were associated with worse disease-specific survival. CONCLUSIONS: Localized and regionally restricted ileojejunal NETs have an excellent prognosis after surgical treatment. Although stage IV tumors cannot be cured, an aggressive surgical approach in combination with medical or interventional treatment can provide long-term survival.
Authors: U Plöckinger; G Rindi; R Arnold; B Eriksson; E P Krenning; W W de Herder; A Goede; M Caplin; K Oberg; J C Reubi; O Nilsson; G Delle Fave; P Ruszniewski; H Ahlman; B Wiedenmann Journal: Neuroendocrinology Date: 2005-04-18 Impact factor: 4.914
Authors: James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans Journal: J Clin Oncol Date: 2008-06-20 Impact factor: 44.544
Authors: Anja Rinke; Hans-Helge Müller; Carmen Schade-Brittinger; Klaus-Jochen Klose; Peter Barth; Matthias Wied; Christina Mayer; Behnaz Aminossadati; Ulrich-Frank Pape; Michael Bläker; Jan Harder; Christian Arnold; Thomas Gress; Rudolf Arnold Journal: J Clin Oncol Date: 2009-08-24 Impact factor: 44.544
Authors: Todd McMullen; Akram Al-Jahdali; Christopher de Gara; Sunita Ghosh; Alexander McEwan; Daniel Schiller Journal: Can J Surg Date: 2017-06 Impact factor: 2.089
Authors: Andreas Selberherr; Simon Freermann; Oskar Koperek; Martin B Niederle; Philipp Riss; Christian Scheuba; Bruno Niederle Journal: Orphanet J Rare Dis Date: 2021-01-14 Impact factor: 4.123
Authors: Joshua M Francis; Adam Kiezun; Alex H Ramos; Stefano Serra; Chandra Sekhar Pedamallu; Zhi Rong Qian; Michaela S Banck; Rahul Kanwar; Amit A Kulkarni; Anna Karpathakis; Veronica Manzo; Tanupriya Contractor; Juliet Philips; Elizabeth Nickerson; Nam Pho; Susanne M Hooshmand; Lauren K Brais; Michael S Lawrence; Trevor Pugh; Aaron McKenna; Andrey Sivachenko; Kristian Cibulskis; Scott L Carter; Akinyemi I Ojesina; Samuel Freeman; Robert T Jones; Douglas Voet; Gordon Saksena; Daniel Auclair; Robert Onofrio; Erica Shefler; Carrie Sougnez; Jonna Grimsby; Lisa Green; Niall Lennon; Tim Meyer; Martyn Caplin; Daniel C Chung; Andreas S Beutler; Shuji Ogino; Christina Thirlwell; Ramesh Shivdasani; Sylvia L Asa; Chris R Harris; Gad Getz; Matthew Kulke; Matthew Meyerson Journal: Nat Genet Date: 2013-11-03 Impact factor: 38.330